Beta-blockers may reduce all-cause mortality in HFpEF patients

Written By : Aditi |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-01-19T11:30:36+05:30 | Updated On 19 Jan 2024 4:33 PM IST

According to the American and European heart failure guidelines, HFpEF is defined as a condition with LVEF >=50% and accompanying signs and symptoms of heart failure, along with elevated left ventricular filling pressures, such as increased natriuretic peptide levels and hemodynamic measurements. It imposes a financial burden, affects healthcare system resource allocation, and is linked to higher morbidity and mortality rates.

According to a recently published meta-analysis, Current Problems in Cardiology, Beta-blockers can decrease all-cause mortality in individuals with heart failure with preserved ejection fraction (HFpEF). However, they did not affect cardiovascular mortality or rehospitalization.

Beta-blockers are commonly used to treat heart failure with reduced ejection fraction, but the same may not apply to HFpEF. This study aimed to evaluate beta-blockers impact on mortality and rehospitalization in HFpEF patients through a systematic review and meta-analysis. The primary outcomes were all-cause and cardiovascular mortality, all-cause and heart failure-related rehospitalization, and a composite of these endpoints.

Key Results from the study are:

Out of the 13,189 records, 16 full-text records met the inclusion criteria and analyzed.
27,188 patients were recruited, with a mean age of 62 – 84 years old, predominantly female, with HFpEF.
63.4% of patients received a beta-blocker, while 36.6% did not.
There was a significant reduction in all-cause mortality by 19% with an odds ratio of 0.81, whereas rehospitalization for heart failure (OR 1.13) or its composite with all-cause mortality (OR 1.01) was similar between the beta-blocker and control groups.

In conclusion, based on observational studies, beta-blockers can potentially reduce all-cause mortality in patients with HFpEF. Nevertheless, rehospitalization for heart failure or its composite with all-cause mortality.

Further investigations are warranted to clarify this uncertainty.

Reference:

Kaddoura, R., Madurasinghe, V., Chapra, A., Abushanab, D., Al‐Badriyeh, D., & Patel, A. (2024). Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis. Current Problems in Cardiology, 102376. https://doi.org/10.1016/j.cpcardiol.2024.102376

adrenergic beta-antagonistsbisoprololcarvediloldiastolic dysfunctionHFpEFmetoprololnebivolol

Source : Current Problems in Cardiology

Aditi

BDS, MDS in Periodontics and Implantology

Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751